Stockreport

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024

Xeris Biopharma Holdings, Inc.  (XERS) 
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am Check Earnings Report
PDF In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate.Lower mUFC at baseline was also [Read more]